(Press-News.org) CHICAGO – Patients with systolic hypertension who were treated with the diuretic chlorthalidone for 4.5 years as part of a clinical trial had a significantly lower rate of death and a gain in life expectancy free from cardiovascular death about 20 years later compared to patients who received placebo, according to a study in the December 21 issue of JAMA.
"Antihypertensive drug therapy has been shown to decrease nonfatal and fatal cardiovascular events in controlled clinical trials and meta-analyses. However, long-term data on gain in life expectancy are not available," according to background information in the article.
John B. Kostis, M.D., of the UMDNJ-Robert Wood Johnson Medical School, New Brunswick, N.J., and colleagues conducted a study to examine the effect of blood pressure (BP) lowering on long-term outcomes such as life expectancy. The researchers obtained long-term mortality data for participants in the Systolic Hypertension in the Elderly Program (SHEP) trial, which was a randomized, placebo-controlled, clinical trial designed to assess the effect of antihypertensive drug treatment (chlorthalidone) in reducing the risk of stroke in patients with isolated systolic hypertension. Recruitment for SHEP was between March 1985 and January 1988. After the end of a 4.5-year randomized phase of the SHEP trial, all participants were advised to receive active therapy. The time interval between the beginning of recruitment and the ascertainment of death (December 2006) was approximately 22 years (21 years 10 months). Of the 4,736 participants enrolled in the SHEP trial, 2,365 (49.9 percent) were randomized to active treatment therapy and 2,371 (50.1 percent) were randomized to placebo. The average age of participants was 72 years, 57 percent were women, and 14 percent were black.
At the end of follow-up, 2,851 of the 4,736 randomized patients (60.2 percent) had died, with 1,416 deaths (59.9 percent) in the active treatment group and 1,435 deaths (60.5 percent) in the placebo group. The researchers found that both life expectancy and time to the 70th percentile survival at the end of follow-up were longer for the SHEP participants who were randomized to the active group compared with those randomized to the placebo group. Life expectancy gain at 22 years was 158 days for cardiovascular death and 105 days for death from all causes. The gain in life expectancy free from cardiovascular death corresponds with 1 day (0.89 days) gained per month of treatment. For all-cause mortality, the gain in life expectancy from 1 month of antihypertensive drug treatment was estimated at a half day (0.59 days).
The authors also found that the active treatment group was associated with higher survival free from cardiovascular death compared with the placebo group (669 deaths [28.3 percent] vs. 735 deaths [31 percent], respectively).
"Reporting that each month of antihypertensive therapy was associated with 1 day prolongation of life expectancy free from cardiovascular death is a strong message that may result in increased patient adherence to drug therapy and decrease the degree of therapeutic inertia by health care providers," the authors write.
###(JAMA. 2011;306[23]:2588-2593. Available pre-embargo to the media at www.jamamedia.org)
Editor's Note: Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.
To contact John B. Kostis, M.D., call Jennifer Forbes at 732-235-6307 or email jenn.forbes@umdnj.edu.
Hypertension treatment associated with long-term improvement in life expectancy
2011-12-21
ELSE PRESS RELEASES FROM THIS DATE:
Findings suggest that severe sepsis can lead to impairment of immune system
2011-12-21
CHICAGO – An analysis of lung and spleen tissue from patients who died of sepsis revealed certain biochemical, cellular and histological findings that were consistent with immunosuppression, according to a study in the December 21 issue of JAMA.
"Sepsis is responsible for more than 225,000 deaths annually in the United States. Developing new therapies for sepsis has been particularly challenging, with more than 25 unsuccessful drug trials. Characterized by an initial intense inflammatory response or 'cytokine storm,' patients with sepsis may present with fever, shock, ...
To turn up the heat in chilies, just add water
2011-12-21
Biologists have learned in recent years that wild chilies develop their trademark pungency, or heat, as a defense against a fungus that could destroy their seeds. But that doesn't explain why some chilies are hot and others are not.
New research provides an answer: Hot chilies growing in dry areas need more water to produce as many seeds as non-pungent plants, but the Fusarium fungus is less of a threat in dryer environments so chilies in those areas are less likely to turn up the heat. In wetter regions, where Fusarium thrives, wild chilies build up their reserves ...
Terahertz pulse increases electron density 1,000-fold
2011-12-21
Kyoto, Japan -- Researchers at Kyoto University have announced a breakthrough with broad implications for semiconductor-based devices. The findings, announced in the December 20 issue of the journal Nature Communications, may lead to the development of ultra-high-speed transistors and high-efficiency photovoltaic cells.
Working with standard semiconductor material (gallium arsenide, GaAs), the team observed that exposing the sample to a terahertz (1,000 gigahertz) range electric field pulse caused an avalanche of electron-hole pairs (excitons) to burst forth. This single-cycle ...
Jackson Design & Remodeling Wins BBB Torch Award for Marketplace Ethics, the Third Consecutive Win for San Diego Remodeling Company
2011-12-21
Jackson Design & Remodeling (JDR) announced today it has won a 2011 Better Business Bureau (BBB) Torch Award for marketplace ethics in the category for San Diego businesses with 25-99 employees. The company won BBB awards in 2007 and 2009. Winning companies are only eligible to submit entries every two years, making this JDR's third consecutive win.
The Torch Awards are the BBB's annual awards program honoring outstanding local for-profit companies and nonprofit charitable organizations that have demonstrated a commitment to ethical business practices, both in operations ...
Frankincense production 'doomed' warn ecologists
2011-12-21
Trees that produce frankincense – used in incense and perfumes across the world and a key part of the Christmas story – are declining so dramatically that production of the fragrant resin could be halved over the next 15 years, according to a new study published in the British Ecological Society's Journal of Applied Ecology.
Ecologists from the Netherlands and Ethiopia say tree numbers could decline by 90% in the next 50 years. If fire, grazing and insect attack – the most likely causes of the decline – remain unchecked frankincense production could be doomed, they warn. ...
Every cloud has a silver lining: Weather forecasting models could predict brain tumor growth
2011-12-21
Every cloud has a silver lining: weather forecasting models could predict brain tumor growth
Ever wondered how meteorologists can accurately predict the weather? They use complex spatiotemporal weather models, i.e. mathematical equations that track the motions of the atmosphere through time and space, and combine them with incoming data streams from weather stations and satellites. Now, an innovative new study published in BioMed Central's open access journal Biology Direct has determined that the mathematical methodology used to assimilate data for weather forecasting ...
Get ready for spring - hay fever worse in spring than summer
2011-12-21
Hay fever (runny nose, sneezing, itchy eyes) is caused by an allergy to pollen, and most commonly to grass pollen. These tiny grains bring misery to sufferers through spring and summer and pollen levels are often included as part of weather reports to help sufferers prepare. However new research published in BioMed Central's open access journal Clinical and Translational Allergy shows that, regardless of medication and other allergies, for the same grass pollen levels, hay fever symptoms are worse in the first half of the season than later on.
Worldwide there are over ...
New candidate vaccine neutralizes all tested strains of malaria parasite
2011-12-21
A new candidate malaria vaccine with the potential to neutralise all strains of the most deadly species of malaria parasite has been developed by a team led by scientists at the University of Oxford. The results of this new vaccine independently confirm the utility of a key discovery reported last month from scientists at the Wellcome Trust Sanger Institute who had identified this target within the parasite as a potential 'Achilles' heel' that could hold significant promise for vaccine development.
According to the World Malaria Report 2010, malaria killed an estimated ...
Can nerve growth factor gene therapy prevent diabetic heart disease?
2011-12-21
Diabetes is a major risk factor for cardiovascular disease and can reduce blood supply to the heart tissue and damage cardiac cells, resulting in heart failure. New research has investigated if nerve growth factor (NGF) gene therapy can prevent diabetic heart failure and small vascular disease in mice.
The study by Professor Costanza Emanueli, British Heart Foundation Senior Research Fellow and colleagues of the Bristol Heart Institute in the Regenerative Medicine Section of the School of Clinical Sciences at the University of Bristol is published online in Diabetes, ...
Fame is more likely to kill rock stars, not being 27 years old
2011-12-21
The list of well known musicians who have died at age 27 may look like more than a coincidence – Amy Winehouse, Jim Morrison, Jimi Hendrix, Janis Joplin, Kurt Cobain, and Brian Jones to name a few – but their age is unlikely to have been the cause of their demise, according to research in the Christmas issue published on bmj.com today.
While fame may increase the risk of death for musicians, probably due to their rock and roll lifestyle, this risk is not limited to age 27, say the authors led by Adrian Barnett from Queensland University of Technology in Australia.
To ...